Vaccination with immunoglobulin frame region-derived nonapeptide elicits cellular immune response against lymphoma in human leukocyte antigen-A2.1 transgenic mice.

Abstract:

:The epitope in the frame region (FR) of the immunoglobulin heavy chain variable region (IgHV) is a potential target for lymphoma immunotherapy. Our previous work identified a FR-derived nonapeptide (QLVQSGAEV) capable of in vitro eliciting anti-lymphoma specific cytotoxic T lymphocytes (CTLs) in lymphocytes from human leukocyte antigen (HLA)-A2.1 donors. Here we used HLA-A2.1 transgenic mice and SCID (severe combined immunodeficiency) mice to confirm the ability of these specific CTLs against lymphomas. We immunized transgenic mice with nonapeptide conjugated to the adjuvant of PADRE (pan HLA DR-binding epitope). The specificity of the elicited CTLs from the immunized transgenic mice was identified by enzyme-linked immunospot (ELISpot) assay and pentamer staining. The elicited CTLs specifically attacked lymphomas with surface IgHV1 in vitro. Adoptive transfer of the CTLs to SCID mice loaded with QLVQSGAEV(+)/HLA-A2.1(+) lymphoma cells effectively inhibited tumor growth. Our results indicate that the relatively constant epitope in the IgHV FR may be useful for immunotherapy of lymphomas with the same IgHV subfamily.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Liu H,Cai P,Liu HX,Wang JL,Liu Q,Zhu P

doi

10.3109/10428194.2011.577257

subject

Has Abstract

pub_date

2011-09-01 00:00:00

pages

1795-802

issue

9

eissn

1042-8194

issn

1029-2403

journal_volume

52

pub_type

杂志文章
  • Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia.

    abstract::Between 1985 and 1990, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) randomized 287 stage B patients between intermittent chlorambucil plus prednisone (n = 140) or CHOP (n = 147), and 90 stage C patients between CHOP (n = 44) or CHOP plus methotrexate (n = 46). In stage B, although treatment respo...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199409049634

    authors:

    更新日期:1994-05-01 00:00:00

  • Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.

    abstract::The mammalian target of rapamycin (mTOR) pathway is a major therapeutic target in the treatment of hematological malignancies, as it controls cellular events of high importance for regulation of mRNA translation and protein production. Rapalogs, or first-generation mTOR inhibitors, have produced only modest clinical b...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1026816

    authors: Mohindra NA,Platanias LC

    更新日期:2015-01-01 00:00:00

  • Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission.

    abstract::The impact of karyotype on the outcome of patients who undergo autotransplant for acute myeloid leukemia (AML) in second remission (CR2) has not been explored. We evaluated the outcomes of 40 patients who proceeded to autotransplant for AML in CR2 at 2 centers. The median age at autotransplant was 50 years (18-64 year...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/10428190400025112

    authors: Song KW,Mollee PN,Hogge DE,Gupta V,Barnett MJ,Forrest DL,Lavoie JC,Nevill TJ,Nantel SH,Shepherd JD,Smith CA,Sutherland HJ,Toze CL,Crump M,Keating A

    更新日期:2005-04-01 00:00:00

  • The role of MDR-1 in refractory lymphoma.

    abstract::Although lymphoma is one of the few solid tumours for which chemotherapy can be curative, the treatment of refractory lymphoma remains a major clinical problem. P-glycoprotein (Pgp), the drug efflux pump encoded by the MDR-1 gene is associated with multidrug resistance in several laboratory models of drug resistance, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709058327

    authors: Sandor V,Wilson W,Fojo T,Bates SE

    更新日期:1997-12-01 00:00:00

  • Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia.

    abstract::Analysis of the microRNA transcriptome following dexa- methasone treatment of the acute lymphocytic leukemia (ALL) cell line RS4;11 showed a global down-regulation of microRNA levels. MIR17HG was rapidly down-regulated following treatment, with chromatin immunoprecipitation (ChIP) analysis demonstrating the promoter t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.678004

    authors: Harada M,Pokrovskaja-Tamm K,Söderhäll S,Heyman M,Grander D,Corcoran M

    更新日期:2012-10-01 00:00:00

  • Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.

    abstract::Low muscle mass (LMM) and low muscle density (LMD) are increasingly recognized as prognostic factors for survival in different malignancies. This study determined the association of LMM and LMD with survival in DLBCL (diffuse large B-cell lymphoma) patients. CT-based measurement of muscle was performed in 164 DLBCL pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1737686

    authors: Rier HN,Kharagjitsing H,van Rosmalen J,van Vugt J,Westerweel PE,de Jongh E,Kock M,Levin MD

    更新日期:2020-07-01 00:00:00

  • Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.

    abstract::We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809068569

    authors: Myers DE,Sicheneder A,Clementson D,Dvorak N,Venkatachalam T,Sev AR,Chandan-Langlie M,Uckun FM

    更新日期:1998-04-01 00:00:00

  • Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiologic staging: a case of disseminated follicular lymphoma detected in nodal clearance as part of therapy for cutaneous melanoma.

    abstract::Patients with localized follicular lymphoma are potentially curable; however, the failure rate for local treatment suggests that a proportion of apparently localized disease is being under-staged. We report a case of incidentally diagnosed follicular lymphoma found in association with a stage II malignant melanoma, wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500305596

    authors: Dickinson M,Wotherspoon A,Cunningham D

    更新日期:2006-03-01 00:00:00

  • Differences Between Long- and Short-Term Survivors with Lymphoma Type of Adult T-Cell Leukemia.

    abstract::The clinical features at time of diagnosis of long-term survivors with lymphoma type of adult T-cell leukemia (ATL) were compared with those of short-term survivors. We had 51 Japanese patients with lymphoma type of ATL from 1981 to 1989 who had human T-cell leukemia virus type I (HTLV-I) antibody and monoclonal integ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009106465

    authors: Shimamot Y,Suga K,Igarashi H,Nishimura J,Nawata H,Yamaguchi M

    更新日期:1990-01-01 00:00:00

  • The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.

    abstract::Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets. It is unclear whether the clinical respons...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500078300

    authors: Strupp C,Germing U,Aivado M,Kündgen A,Fenk R,Hünerlitürkoglu A,Kobbe G,Haas R,Gattermann N

    更新日期:2005-07-01 00:00:00

  • Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

    abstract::Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF, the US indication...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1195501

    authors: Harrison CN,Talpaz M,Mead AJ

    更新日期:2016-10-01 00:00:00

  • Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.

    abstract::During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109060343

    authors: Lindauer M,Fischer T

    更新日期:2001-05-01 00:00:00

  • DNA methylation patterns of adult survivors of adolescent/young adult Hodgkin lymphoma compared to their unaffected monozygotic twin.

    abstract::DNA methylation (DNAm) silences gene expression and may play a role in immune dysregulation that is characteristic of adolescent/young adult Hodgkin lymphoma (AYAHL). We used the Infinium HumanMethylation27 BeadChip to quantify DNAm in blood (N = 9 pairs, mean age 57.4 y) or saliva (N = 36 pairs, mean age 50.0 y) from...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1533128

    authors: Wang J,Van Den Berg D,Hwang AE,Weisenberger D,Triche T,Nathwani BN,Conti DV,Siegmund K,Mack TM,Horvath S,Cozen W

    更新日期:2019-06-01 00:00:00

  • Multiple myeloma associated with lactic acidosis.

    abstract::Type B lactic acidosis is rare among patients with malignant diseases. To date only one case report has documented lactic acidosis occurring in a patient with multiple myeloma (MM). Our patient, a 55-year-old black man, was diagnosed with stage IIIA immunoglobulin G-kappa (IgG-kappa) MM in September 1995. He was found...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000040116

    authors: Ustun C,Fall P,Szerlip HM,Jillella A,Hendricks L,Burgess R,Dainer P

    更新日期:2002-12-01 00:00:00

  • Hematological toxicities associated with amphotericin B formulations.

    abstract::Even though amphotericin B is associated with considerable hematological toxicity, this subject has been poorly studied. This retrospective cohort study assessed the incidence and predictors of hematological toxicity in patients treated with different amphotericin B formulations: amphotericin B deoxycholate (d-AmB), l...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1010080

    authors: Falci DR,da Rosa FB,Pasqualotto AC

    更新日期:2015-01-01 00:00:00

  • Non-Hodgkin's lymphoma and pregnancy.

    abstract::Non-Hodgkin's lymphoma (NHL) is infrequently diagnosed during pregnancy. Most NHL's complicating pregnancy are aggressive and disseminated. This presentation together with the possible teratogenecity of diagnostic methods dictate a limited staging workup during pregnancy. Although prognosis had been reported to be poo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409049697

    authors: Lishner M,Zemlickis D,Sutcliffe SB,Koren G

    更新日期:1994-08-01 00:00:00

  • Acute myelogenous leukemia associated with a mediastinal tumor.

    abstract::We describe a 45-year-old female who developed acute myelogenous leukemia (AML) associated with a mediastinal mass. The patient achieved a complete remission accompanied by resolution of the mediastinal mass following intensive chemotherapy alone. A review of the literature disclosed ten AML patients with a mediastina...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309059583

    authors: Chubachi A,Miura I,Takahashi N,Nimura T,Imai H,Miura AB

    更新日期:1993-12-01 00:00:00

  • Techniques for detection of minimal residual disease.

    abstract::Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characte...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509075308

    authors: Carlo-Stella C,Mangoni L,Dotti GP,Rizzoli V

    更新日期:1995-01-01 00:00:00

  • Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

    abstract::A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regime...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000151923

    authors: Tsutsumi Y,Kawamura T,Saitoh S,Yamada M,Obara S,Miura T,Kanamori H,Tanaka J,Asaka M,Imamura M,Masauzi N

    更新日期:2004-03-01 00:00:00

  • Acute promyelocytic leukemia, hypogranular variant, with uncharacteristic staining with chloroacetate esterase.

    abstract::A diagnosis of the hypogranular variant of acute promyelocytic leukemia (APLv) may be difficult to establish based on cytomorphology alone. However, the great majority of cases have a classical immunophenotype by flow cytometric immunophenotyping (FCI) (CD13+, CD33+, dim CD64+, HLA-DR-, and CD34-) and a classical enzy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097693

    authors: Dunphy CH,Polski JM,Johns G,Evans HL,Gardner LJ

    更新日期:2001-06-01 00:00:00

  • Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus.

    abstract::Abstract Everolimus (RAD-001) has recently been used as an immunosuppressive drug to treat patients after hematopoietic stem cell transplant (HSCT), thereby reducing cyclosporine-related nephrotoxicity. We studied the immunomodulatory effect of everolimus on mitogen-stimulated and particularly cytomegalovirus (CMV)-sp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.822496

    authors: Jin N,Malcherek G,Mani J,Zurleit R,Schmitt A,Chen B,Freund M,Ho AD,Schmitt M

    更新日期:2014-05-01 00:00:00

  • Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes.

    abstract::Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematologi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1028053

    authors: Sánchez-Castro J,Marco-Betés V,Gómez-Arbonés X,García-Cerecedo T,López R,Talavera E,Fernández-Ruiz S,Ademà V,Marugan I,Luño E,Sanzo C,Vallespí T,Arenillas L,Marco Buades J,Batlle A,Buño I,Martín Ramos ML,Blázquez Rios B

    更新日期:2015-01-01 00:00:00

  • Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.

    abstract::The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819021000016078

    authors: Roboz GJ,Knovich MA,Bayer RL,Schuster MW,Seiter K,Powell BL,Woodruff RD,Silver RT,Frankel AE,Feldman EJ

    更新日期:2002-10-01 00:00:00

  • Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphoma in South Florida and review of the literature.

    abstract::The etiology of non-Hodgkin's lymphoma is unknown in the majority of the cases. Although Epstein-Barr virus, human T-cell leukemia-lymphoma virus and human herpes virus-8 have been established as casual agents in the pathogenesis of specific types of lymphoma, the role of hepatitis C virus (HCV) in lymphomagenesis rem...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400007771

    authors: Morgensztern D,Rosado M,Silva O,Santos E,Abdullah S,Goodman M,Hamilton-Nelson K,Rosenblatt J,Lossos I

    更新日期:2004-12-01 00:00:00

  • Endogenous murine leukemia virus DNA sequences in murine cell lines: implications for gene therapy safety testing by PCR.

    abstract::Safety testing for replication-competent retrovirus (RCR) is an important requirement in gene transfer clinical trials using retroviral vectors. A sensitive polymerase chain reaction (PCR) method is one approach to RCR detection. Only in the presence of RCR will the pol-env encoding sequences, necessary for viral repl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609054842

    authors: Allan DS,De Koven A,Wild A,Kamel-Reid S,Dubé ID

    更新日期:1996-10-01 00:00:00

  • Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data.

    abstract::There is little evidence about whether additional risk stratification for adult patients with acute lymphoblastic leukemia age 65 and older is warranted. Using the Surveillance, Epidemiology, and End Results data linked to Medicare claims, we examined the effects of age, comorbid conditions, and mobility limitations o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1555329

    authors: Danese MD,Katz A,Cetin K,Chia V,Gleeson ML,Kelsh M,Griffiths RI

    更新日期:2019-08-01 00:00:00

  • Clinical significance of detecting p53 protein in Burkitt lymphoma and B-cell acute lymphoblastic leukemia using immunocytochemistry.

    abstract::P53 protein expression in malignant cells of five patients with Burkitt lymphoma (BL) and from two patients with B-cell acute lymphoblastic leukemia (B-ALL) was examined with anti p53 protein monoclonal antibodies PAb1801, PAb240 and p53-D07 using an immunocytochemical technique. Four of the seven patients were positi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809058368

    authors: Nagai J,Kigasawa H,Koga N,Katoh A,Nishihira H,Nagao T

    更新日期:1998-02-01 00:00:00

  • Clinicopathological analysis of follicular lymphoma with a polyploid karyotype.

    abstract::The prognostic significance of specific cytogenetic abnormalities in follicular lymphoma (FL) is an area of ongoing research. A small percentage of FL are characterized by a polyploid karyotype. Several studies have analyzed ploidy level to determine its role as an independent prognostic factor in non-Hodgkins lymphom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809092694

    authors: James GK,Horsman D,Connors JM,Klasa R,Wilson K,Argatoff L,Gascoyne RD

    更新日期:1998-01-01 00:00:00

  • Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.

    abstract::B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006411

    authors: Wang P,Pavletic ZS,Joshi SS

    更新日期:2002-09-01 00:00:00

  • Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

    abstract::Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1205741

    authors: Pozzi S,Gentile M,Sacchi S,Marcheselli R,Corso A,Cocito F,Musto P,Guarini A,Minoia C,Vincelli I,Ria R,Rivolti E,Mele G,Bari A,Mazzone C,Badiali S,Marcheselli L,Palumbo A,Morabito F

    更新日期:2017-03-01 00:00:00